Bone Deformity Clinical Trial
Official title:
Mg-containing Biodegradable Polymer Bone Repair Material
The subjects of this study are patients with non-load-bearing bone defects of the extremities who need bone grafting surgery. The patients was treated with bone graft using magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.. Three follow-up visits were performed at the 12th, 24th and 36th weeks after bone grafting, the clinical role for bone will be assessed.
Status | Recruiting |
Enrollment | 176 |
Est. completion date | March 31, 2024 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age = 18 years old and = 75 years old, regardless of gender; 2. Bone defect exists in one of the following anatomical positions, and bone grafting is required: Upper limb bones: humerus, ulna, radius, metacarpus, carpus, phalanges; Lower limb bones: femur, tibia, fibula, calcaneus, navicular bone, wedge bone, cuboid bone, metatarsal bone, talus and phalanges; 3. The maximum diameter of the expected or actual three-dimensional bone defect is = 0.5cm and = 6cm, and the defect is only one; 4. The bone defect site is expected to be fixed with non-degradable internal fixation system during operation; 5. Subjects or their legal representatives can understand the purpose of the study and show sufficient compliance with the study protocol and sign the informed consent form. Exclusion Criteria: 1. The blood glucose control is unstable and cannot meet the operation conditions; 2. Severe coagulation dysfunction (PT or APTT = 2 times the upper limit of normal value); 3. History of arterial thrombosis attack (such as stroke, angina pectoris, acute myocardial infarction, etc.) or NYHA grade = III within 3 months before enrollment; 4. Oral or injection of sedative and hypnotic drugs or non-steroidal anti-inflammatory drugs (except aspirin) every week within 3 months before enrollment; 5. He had received chemotherapy drugs or radiotherapy within 3 months before admission; 6. Cumulative oral or injection of corticosteroids or various growth factors for = 14 days within 1 month before enrollment; 7. Suffering from systemic infection or uncontrollable local infection, serious soft tissue injury at the proposed operation site, serious vascular or nerve injury, malignant tumor, confirmed severe malnutrition or other important organ failure; 8. The limb to be operated on has osteofascial compartment syndrome; 9. Structural bone grafting is required; 10. Pregnant or lactating women; 11. Participate in clinical trials of other drugs or medical devices within one month before enrollment; 12. For the benefit of the subject, the researcher believes that it should not participate in other situations of this clinical trial. |
Country | Name | City | State |
---|---|---|---|
China | Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd | Shenzhen | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd | Chinese University of Hong Kong, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bone graft fusion rate | When Mg-containing degradable polymer bone repair material is used to repair non-load-bearing bone defects of limbs, the main effective evaluation index is bone graft fusion rate at 24 weeks after operation | 24 weeks after standard operation | |
Secondary | to evaluate the bone graft fusion rate | to evaluate the bone graft fusion rate at 12 and 36 weeks after operation | 12 and 36 weeks after operation | |
Secondary | Improvement level of SF-36 scale and satisfaction of device operation | Improvement level of SF-36 scale and satisfaction of instrument operation at 36 weeks after operation | at 36 weeks after operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03076138 -
Gene-activated Bone Substitute for Maxillofacial Bone Regeneration
|
N/A | |
Recruiting |
NCT03570606 -
Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications.
|
||
Completed |
NCT01738113 -
Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD
|
Phase 2 | |
Active, not recruiting |
NCT06312384 -
The Influence of 3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation
|
Phase 3 | |
Not yet recruiting |
NCT05676905 -
Prospective Multicenter Observational Study on the Use of NEOCEMENT® for the Treatment of Bone Defects
|
||
Active, not recruiting |
NCT05659069 -
Influence of Mandibular Nerve Lateralization on Nutrition and Speech
|